For Serum Bactericidal Activity against Neisseria Meningitidis

Ala’Aldeen, D. A. et al. (2000) “Dynamics of meningococcal long term carriage among university students and their implications for mass vaccination” J Clin Microbiol 38(6):2311-2316. Andrews, N et al. (2003) “Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England” Clin Diagn Lab Immunol 10(5):780-786. Ashton, F. E. et al. (1989) “Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide” Microb Pathog 6(6);455-458. Balmer & Borrow (2004) “Serologic correlates of protection for evaluating the response to meningococcal vaccines” Expert Rev Pac cines 3(1):77-87. Bogaert, D. et al. (2005) “Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children.” Clin Infect Dis 40(6):899-902. Borrow, R. et al. (2001) “Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection” Infect Immun 69(3):1568-1573. Borrow, R. et al. (2005) “Meningococcal surrogates of protection— serum bactericidal antibody activity” Vaccine 23(17-18):2222-2227. Fischer, et al. (1999) “Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease” Vaccine 17(19):2377-2383. Fletcheretal. (2004) “Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.” Infect. Immun. 72(4):2088-2100. GenBank Accession No. EU888587 “Ovis aries complement factor H (CFH) mRNA, partial cds” dated Aug. 18, 2008. GenBank Accession No. NM 000186 “Homo sapiens complement factor H (CFH), nuclear gene encoding mitochondrial protein, tran script variant 1, mRNA” dated Aug. 24, 2008. GenBank Accession No. NM 001014975 “Homo sapiens comple ment factor H (CFH), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA” dated Aug. 24, 2008. GenBank Accession No. NM 009888 “Mus musculus complement component factor h (CfFI), nuclear gene encoding mitochondrial protein, mRNA” dated Feb. 11, 2008. Goldschneider et al. (1969) “Human immunity to the meningococ cus. I. The role of humoral antibodies” J. Exp. Med 129(6): 1307 1326. Goldschneider, et al. (1969) “Human immunity to the meningococ cus. I. Development of natural immunity” J Exp Med 129(6):1327 1348. Granoff (2009) “Relative importance of complement-mediated bac tericidal and opsonic activity for protection against meningococcal disease” Vaccine 27(Suppl. 2):B117-125. doi:10.1016/j.vaccine. 2009.04,066. Harris, S. L. et al. (2003) “Age-related disparity in functional activi ties of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine” Infect. Immun. 71(1):275 286. Holbein, et al. (1979) “Neisseria meningitidis infection in mice: influence of iron, variations in virulence among strains, and pathol ogy” Infect Immun. 24(2):545-551. Jodar, L. et al. (2000) “Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines” Biologicals 28(3):193 197. Maiden, et al. (2008) “Impact of meningococcal serogroup C conju gate vaccines on carriage and herd immunity” J. Infect. Dis. 197(5):737-743. Mountzouros & Howell (2000) “Detection of ComplementMediated Antibody-Dependent Bactericidal activity in a Fluorescence-Based Serum Bactericidal Assay for Group B Neisseria meningitidis.” J. Clin. Microbiol. 38(3):2878-2884. Mueller, etal. (2007) “Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003” Emerg. Infect. Dis. 13(6):847-854. Oster, et al. (2007) “Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand” Vaccine 25(16):3075-3079. Perkins, et al. (1998) “Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland” J. Infect. Dis. 177(3):683-691.